Enlivex Therapeutics Ltd.
ENLV | NASDAQ
$1.29
-$0.10 (-7.19%)
At close: Nov 5, 2026, 3:59 PM ET
$1.35
+$0.06 (+4.65%)
After-hours:
Nov 5, 2026, 5:16 PM ET
Market Data
Market Cap $21.71M
Enterprise Value $35.13M
Beta 1.41
Average Volume 52.5K
Shares Outstanding (Diluted) 1.21M
Shares Change YoY 1115.64%
Institutional Ownership 9.35%
Exchange NASDAQ
ISIN IL0011319527
Price Performance
Price Change 1M -76.3%
Price Change 3M -95.9%
Price Change 6M -99.3%
Price Change YTD -99.2%
Price Change 1Y -99.5%
Price Change 3Y -99.7%
Price Change 5Y -99.9%
1M CAGR (ann.) -87.3%
1Y CAGR (ann.) -99.4%
5Y CAGR (ann.) -76.8%
All-Time CAGR -60.2%
Valuation
PE Ratio 0.00
Forward PE N/A
PEG Ratio 0.00
Forward PEG -0.00
PS Ratio N/A
Forward PS N/A
PB Ratio 0.01
P/FCF Ratio -1.45
P/Adj. FCF Ratio -1.35
P/OCF Ratio -0.11
EV/Sales N/A
EV/EBIT -1.74
EV/EBITDA -1.76
EV/FCF -2.17
Earnings Yield 618728.1%
FCF Yield -69.1%
Adj. FCF Yield -74.2%
Financial Health
Net Debt $11.36M
Total Debt $17.25M
Cash & Short-Term Investments $5.52M
Total Assets $4.9B
Current Ratio 119.39
Quick Ratio 119.39
Debt / Equity Ratio 0.00
Debt / EBITDA -0.87
Debt / FCF -1.07
OCF / Debt -0.92
Interest Coverage -15.46
Altman Z-Score 1.78
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -7.4%
Returns
Return on Assets 83.8%
Return on Equity 211.0%
Return on Invested Capital -0.3%
Return on Capital Employed -0.4%
Return on Tangible Assets 109.4%
Historical Growth (CAGR)
Revenue CAGR 3Y N/A
Revenue CAGR 5Y N/A
Revenue CAGR 10Y -6.1%
EPS CAGR 3Y 163.1%
EPS CAGR 5Y 123.1%
EPS CAGR 10Y 203.0%
FCF CAGR 3Y 2.3%
FCF CAGR 5Y 19.9%
FCF CAGR 10Y -10.4%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 2
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Nov 13, 2026
EPS Estimate (next Q) -$4.48
EPS Growth Est (next Q) 155.3%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number $24,986
Graham Upside 1797420.9%
Lynch Fair Value $215,008
Lynch Upside 15468101.4%
Price Target $15.00
Price Target Upside 979.1%
Cash Flow
Operating Cash Flow $-15.8M
Free Cash Flow $-16.17M
Adj. Free Cash Flow $-17.37M
FCF Per Share -$13.39
OCF Per Share -$13.08
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $-214K
Operating Income $-20.56M
EBITDA $-19.93M
Net Income $4.11B
EPS (Diluted) $8,600.32
Revenue / Employee N/A
Profit / Employee $120.79M
Employees 34
Add to Watchlist
Select watchlists to add or remove ENLV